Jupiter Life Line Hospitals Limited — Q1 FY26 earnings call

Call held 4 Aug 2025

Management summary

Jupiter Life Line Hospitals reported a strong Q1 FY26 with total income growing 20.5% and EBITDA up 19.6%. However, PAT saw a slight decline of 1.6% due to higher depreciation and finance costs, a trend expected to continue. The company is progressing on greenfield projects and commissioned a new solar plant, while maintaining a net cash position. Occupancy rates saw a relative dilution due to new bed additions, but absolute occupancy and patient volumes increased.

Highlights

  • Total income grew 20.5% YoY to ₹347.6 crores, including ₹6.6 crores from Jupiter Pharmacy.

  • EBITDA increased 19.6% YoY to ₹78.1 crores, maintaining a healthy margin of 22.5%.

  • Company maintains a net cash position of ₹275 crores, with total debt at ₹325 crores and cash at ₹600 crores.

  • Overall patient volume increased by 11.7% YoY to 2.6 lakhs.

  • Commissioned a new 1.2 megawatt solar power plant, contributing to annual opex savings of ~₹1 crore.

Concerns

  • PAT decreased by 1.6% YoY, with PAT margin at 12.6%.

  • The gap between PAT and EBITDA is expected to widen for the full financial year due to increased depreciation and finance costs.

  • Average occupancy rate declined to 60.1% in Q1FY26 from 63.9% last year, attributed to increased Census Beds.

  • Thane hospital bed expansion is delayed due to regulatory issues (Environment Committee applications not being accepted).

Key financials

  1. Total Income ₹347.6 Cr +20.5%YoY
  2. EBITDA ₹78.1 Cr +19.6%YoY
  3. EBITDA Margin 22.5%
  4. PAT — -1.6%YoY
  5. PAT Margin 12.6%
  6. ARPOB ₹67,300
  7. ALOS 3.78 days
  8. Occupancy Rate 60.1%
  9. Patient Volume ₹2.6 lakh +11.7%YoY

What they filed

Q1 FY27: revenue up 16.4%, net profit down 13.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue335 333 337 353 394 +18%365 +10%388 +15%411 +16%
EBITDA78 76 80 78 92 +18%83 +9%89 +11%79 +1%
Net profit52 52 45 44 57 +10%42 −19%50 +11%38 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex Capex disclosed
    • Dombivli greenfield hospital (remaining capex) ₹200 Cr
    • Indore solar plant ₹5 Cr
    • Pune-Baner new ICU
    Dombivli: "I think we have incurred something around INR200 crores of expenditure already till now, and we should incur similar, around INR200 crores more, in the next few months till we start the Dombivli hospital." Indore Solar: "So Indore solar plant has cost us about roughly INR5 crores in capex."
  • Debt Gross ₹325 Cr
    Net debt is still 0. The total debt is INR325 crores, and the cash position is something in the zip code of INR600 crores. So, we are net cash of INR275 crores.
  • Liquidity Cash ₹600 Cr Company is net cash of INR275 crores.
    Net debt is still 0. The total debt is INR325 crores, and the cash position is something in the zip code of INR600 crores. So, we are net cash of INR275 crores.

Guidance & targets

Capex

  • Dombivli remaining capex Capex · next few months (by Q1 next year) · High confidence ~INR200 crores
    I think we have incurred something around INR200 crores of expenditure already till now, and we should incur similar, around INR200 crores more, in the next few months till we start the Dombivli hospital.

    — Ankit Thakker

Profitability

  • Dombivli EBITDA Profitability · first year · High confidence Negative
    first year, Dombivli should have negative EBITDA to some number.

    — Ankit Thakker

  • Dombivli EBITDA breakeven Profitability · by year 2 · High confidence Breakeven
    current thought is by year 2, we should breakeven on an EBITDA level.

    — Ankit Thakker

  • PAT-EBITDA gap Profitability · this financial year · High confidence Widen
    the gap between PAT and EBITDA is expected to widen, leading to lower PAT margins this year.

    — Ankit Thakker

  • Dombivli EBITDA burn Profitability · Medium confidence ~INR2-2.5 crores a month
    So in the past, the experience has been around INR2 crores, INR2.5 crores a month. I think we should be similar.

    — Ankit Thakker

Growth

  • Pune and Indore growth Growth · this financial year · Medium confidence More growth than Thane
    you should see some growth for Pune and Indore more than for Thane in this financial year before Dombivli starts contributing from next year.

    — Ankit Thakker

Capacity

  • Pune-Baner new ICU commissioning Capacity · towards the end of the year · Medium confidence Commissioned
    Maybe sometime towards the end of the year, it should get commissioned.

    — Ankit Thakker

  • Maharashtra solar capacity addition Capacity · Medium confidence 3 megawatts
    we are in advanced stages of discussing 3 megawatts of solar in Maharashtra as well.

    — Ankit Thakker

Occupancy

  • Peak occupancy for all hospitals Occupancy · High confidence Mid-70% range
    So all the hospitals, we expect the peak to be in the mid-70% range.

    — Ankit Thakker

Opex Savings

  • Indore solar plant annual opex savings Opex Savings · annually · High confidence ~INR1 crore
    It is expected to result in around INR1 crore in opex savings annually with a lifetime of 20, 25 years.

    — Ankit Thakker

Operational Metric

  • ALOS trend Operational Metric · High confidence Around 4 days
    But the trend has been over the last several quarters to be in this zip code of around 4 days.

    — Ankit Thakker

What to watch in Q2 FY26

Dombivli capex completion and commissioning

next few months (by Q1 next year)
Current INR200 crores incurred, INR200 crores more needed
Target Substantial completion of remaining capex and progress towards commissioning

Why it matters

Timely completion of Dombivli is crucial for future revenue streams and achieving EBITDA breakeven by year 2.

I think we have incurred something around INR200 crores of expenditure already till now, and we should incur similar, around INR200 crores more, in the next few months till we start the Dombivli hospital.

Risks & concerns

  • Regulatory delays for Thane bed expansion

    medium

    Government not accepting Environment Committee applications due to a Supreme Court case, delaying new bed additions.

    Management acknowledged

  • Negative EBITDA from new Dombivli hospital

    medium

    Dombivli is expected to have negative EBITDA in its first year, leading to some compression at the consolidated level.

    Management acknowledged

  • Widening PAT-EBITDA gap and lower PAT margins

    medium

    Increased depreciation (over ₹10 crores this quarter) and finance costs will widen the gap between PAT and EBITDA, leading to lower PAT margins for the financial year.

    Management acknowledged

Q&A highlights

7 direct
Thane hospital bed expansion status and regulatory hurdles Direct
No. So there is no update on that front. The government is still not accepting applications in the Environment Committee from Thane. There is some Supreme Court story going on because of which new environmental permissions in Thane are not being granted to anybody.

Reveals a significant regulatory roadblock impacting capacity expansion plans for an existing facility.

Asked by Abdulkader

Impact of Dombivli hospital on consolidated margins Direct
first year, Dombivli should have negative EBITDA to some number... But on a consolidated level next year, there should be some compression on account of Dombivli.

Provides clear guidance on the near-term financial impact of a new greenfield project on overall company profitability.

Asked by Parth Singhal

Drivers of ARPOB growth (case mix vs. price hikes) Direct
price hike is a factor in all the 3 locations. That is inflation-linked price hike... For Indore, especially, there will be a factor of case mix optimization as well because it is still not a matured hospital. So, it is a little bit of combination of case mix and price hike both, which are giving rise to ARPOB.

Clarifies the components of ARPOB growth, indicating both pricing power and strategic case mix improvement, particularly in newer facilities.

Asked by Amey Chalke

Payor mix shift towards insurance and its sustainability Direct
I think this is going to be a kind of lasting trend nationwide. The insurance penetration is increasing year-on-year everywhere in the country, and that will get reflected in the patients who walk into our facilities also. So, I think this trend -- I don't know at what speed, but I think this trend is likely to continue.

Highlights a structural shift in the healthcare market towards insurance-based payments, which can impact revenue realization and collection cycles.

Asked by Abdulkader

Timeline for Dombivli Phase 2 commissioning Direct
current thought is by year 2, we should breakeven on an EBITDA level. And after that, depending on how fast the occupancy ramps up, we will think of Phase 2. The thumb rule that we work by is once we have reached 60-odd percent occupancy at the installed base, we start commissioning work on Phase 2.

Provides a clear operational trigger and timeline for future capacity expansion at the new Dombivli facility.

Asked by Dheeresh

Impact of new peer hospital in Thane on volumes and HR Direct
No. So, there is no impact on volumes or HR because of that. And our occupancies and performance are tracking in line as they were before.

Reassures investors about competitive pressures in a key market, indicating the company's established position is resilient.

Asked by Anjana Shah

PAT expectation for the financial year given increased costs Partial
As I said, the gap between EBITDA and PBT or EBITDA and PAT should be a little wider on account of depreciation and finance cost. In absolute terms, I don't have an expectation currently.

Management acknowledges the impact of higher costs on PAT but refrains from providing a specific numerical guidance, indicating uncertainty or conservatism.

Asked by Saurabh Bhole

Dombivli's 2-year EBITDA burn estimate Direct
So in the past, the experience has been around INR2 crores, INR2.5 crores a month. I think we should be similar. But once we have operated for about 1 or 2 quarters, maybe we'll understand better.

Provides a historical benchmark for initial operational losses of new facilities, offering a quantitative expectation for Dombivli's ramp-up phase.

Asked by Dheeresh

3 min read 6 chapters

Detailed narrative

Q1 FY26 Financial Performance Overview

Jupiter Life Line Hospitals reported a robust Q1 FY26 with total income reaching ₹347.6 crores, marking a 20.5% year-on-year increase. EBITDA also grew significantly by 19.6% to ₹78.1 crores, maintaining a healthy margin of 22.5%. However, Net Profit (PAT) saw a slight decline of 1.6% year-on-year, resulting in a PAT margin of 12.6%. This PAT compression is primarily attributed to increased depreciation and finance costs, a trend management expects to continue for the full financial year.

Greenfield Projects and Capacity Expansion

The company's three greenfield projects in Dombivli, Mira Road, and the second Pune Hospital are progressing as planned. For Dombivli, approximately ₹200 crores has been incurred, with another ₹200 crores expected in the coming months to reach completion. The Pune-Baner facility is set to commission a new ICU towards the end of the year. Management indicated that Pune and Indore, benefiting from increased capacity, are expected to drive more growth than Thane this financial year.

Operational Metrics and Payor Mix

Operational metrics for Q1 FY26 showed an average occupancy rate of 60.1%, a relative dilution compared to 63.9% last year due to the addition of new Census Beds. However, absolute occupancy and overall patient volume increased by 11.7% year-on-year to 2.6 lakhs. The Average Revenue Per Occupied Bed (ARPOB) stood at ₹67,300, driven by a combination of inflation-linked price hikes across all locations and case mix optimization, particularly in the less mature Indore hospital. The payor mix saw 56.3% from insurance, 42.3% from self-payers, and 1.4% from government schemes, with management noting a lasting nationwide trend of increasing insurance penetration.

Capital Allocation and Debt Profile

Jupiter Life Line Hospitals maintains a strong liquidity position with a net cash balance of ₹275 crores, comprising ₹600 crores in cash against a total debt of ₹325 crores. Capital expenditure for Dombivli is expected to require an additional ₹200 crores in the near term. The company also invested ₹5 crores in a new 1.2 megawatt solar power plant in Madhya Pradesh, which is projected to yield annual opex savings of approximately ₹1 crore over its 20-25 year lifespan. Discussions are also underway to add 3 megawatts of solar capacity in Maharashtra.

Future Outlook and Margin Expectations

Management anticipates that while EBITDA margins will likely be preserved, the widening gap between PAT and EBITDA due to higher depreciation and finance costs will lead to lower PAT margins for the full financial year. The new Dombivli hospital is expected to incur negative EBITDA in its first year of operation, causing some compression at the consolidated level, but is targeted to achieve EBITDA breakeven by its second year. Peak occupancy for all hospitals is expected to be in the mid-70% range.

Regulatory Challenges and Competitive Landscape

A significant regulatory challenge was highlighted regarding the planned bed expansion at the Thane hospital, where the Environment Committee is not accepting applications due to an ongoing Supreme Court case, leading to an indefinite delay. Despite a new peer hospital commencing operations in Thane, management confirmed no impact on Jupiter's patient volumes or human resources, with performance remaining in line with previous trends.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls